SCHEMBL2022486

SCHEMBL2022486

O=C1c2c(Cl)cc(-c3cnccn3)cc2CN1Cc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHPS P49366 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
P2RX7 Q99572 3/20 0.36
ADAM17 P78536 1/20 0.36
USP2 O75604 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
FAAH O00519 2/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
TRPV6 Q9H1D0 1/20 0.34
PARP1 P09874 1/20 0.34
CYP2C9 P11712 1/20 0.34
PPARG P37231 1/20 0.34
TNIK Q9UKE5 1/20 0.34
MGLL Q99685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2026906 0.90 GRM2 (0.42) DHPSMEN1KMT2AP2RX7ADAM17
SCHEMBL2027096 0.89 MAPK1 (0.38) ADAM17FAAHPARP1CYP2C9PPARG
SCHEMBL2021064 0.87 DHPS (0.47) DHPSMEN1KMT2AUSP2TP53
SCHEMBL2021175 0.84 GRM2 (0.41) DHPSMEN1KMT2AP2RX7ADAM17
SCHEMBL1090522 0.82 GRM2 (0.40) MEN1KMT2AP2RX7ADAM17USP2
SCHEMBL1091638 0.81 GRM2 (0.43) MEN1KMT2AP2RX7ADAM17USP2
SCHEMBL1091626 0.81 GRM2 (0.40) MEN1KMT2AP2RX7ADAM17USP2
SCHEMBL2025256 0.81 LTA4H (0.39) ADAM17FAAHPARP1CYP2C9PPARG
SCHEMBL1092468 0.80 GRM2 (0.40) MEN1KMT2AP2RX7ADAM17USP2
SCHEMBL2022274 0.79 GRM2 (0.43) MEN1KMT2AADAM17PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 DHPS 2532/4885MEN1 2588/4885KMT2A 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.